Gene Rv0678
in Mycobacterium tuberculosis H37Rv
General annotation
| Type | CDS |
| Function | Function unknown |
| Product | Conserved protein |
| Comments | Rv0678, (MTV040.06), len: 165 aa. Conserved protein, showing weak similarity with AL049754|SCH10_10 hypothetical protein from Streptomyces coelicolor (152 aa), FASTA scores: opt: 149, E(): 0.0018, (22.9% identity in 140 aa overlap). |
| Functional category | Conserved hypotheticals |
| Proteomics | Identified by mass spectrometry in Triton X-114 extracts of M. tuberculosis H37Rv (See Malen et al., 2010). Identified by mass spectrometry in the membrane protein fraction and whole cell lysates of M. tuberculosis H37Rv but not the culture filtrate (See de Souza et al., 2011). |
| Transcriptomics | mRNA identified by microarray analysis and down-regulated after 4h of starvation (see citation below). DNA microarrays and qRT-PCR show higher expression of Rv0676c, Rv0677c and Rv0678 in azole-resistant H37Rv mutant than in wild-type (See Milano et al., 2009). |
| Mutant | Non-essential gene for in vitro growth of H37Rv in a MtbYM rich medium, by Himar1 transposon mutagenesis (see Minato et al. 2019). Non-essential gene for in vitro growth of H37Rv, by analysis of saturated Himar1 transposon libraries (see DeJesus et al. 2017). Non-essential gene for in vitro growth of H37Rv, by Himar1 transposon mutagenesis (See Griffin et al., 2011). Azole-resistant H37Rv mutant has mutations in Rv0678 (See Milano et al., 2009). Check for mutants available at TARGET website |
Coordinates
| Type | Start | End | Orientation |
|---|---|---|---|
| CDS | 778990 | 779487 | + |
Genomic sequence
Feature type
Upstream flanking region (bp)
Downstream flanking region (bp)
Update
Protein sequence
>Mycobacterium tuberculosis H37Rv|Rv0678|Rv0678
VSVNDGVDQMGAEPDIMEFVEQMGGYFESRSLTRLAGRLLGWLLVCDPERQSSEELATALAASSGGISTNARMLIQFGFIERLAVAGDRRTYFRLRPNAFAAGERERIRAMAELQDLADVGLRALGDAPPQRSRRLREMRDLLAYMENVVSDALGRYSQRTGEDD
Bibliography
- Betts JC et al. [2002]. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Transcriptome
- Milano A et al. [2009]. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Mutant Transcriptome
- Målen H et al. [2010]. Definition of novel cell envelope associated proteins in Triton X-114 extracts of Mycobacterium tuberculosis H37Rv. Proteomics
- de Souza GA et al. [2011]. Bacterial proteins with cleaved or uncleaved signal peptides of the general secretory pathway. Proteomics
- Griffin JE et al. [2011]. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. Mutant
- Mazandu GK et al. [2012]. Function prediction and analysis of mycobacterium tuberculosis hypothetical proteins. Function
- Hartkoorn RC et al. [2014]. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Mutant Function Regulation
- Radhakrishnan A et al. [2014]. Crystal structure of the transcriptional regulator Rv0678 of Mycobacterium tuberculosis. Structure Function
- Andries K et al. [2014]. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. Mutant
- Zhang S et al. [2015]. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. Regulation Clinical
- Almeida D et al. [2016]. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Clinical
- DeJesus MA et al. [2017]. Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis. Mutant
- Villellas C et al. [2017]. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. Regulation Clinical
- Xu J et al. [2017]. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Clinical
- Zimenkov DV et al. [2017]. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. Clinical
- Pang Y et al. [2017]. In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. Clinical
- Xu J et al. [2018]. Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis. Clinical
- Nguyen TVA et al. [2018]. Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. Secondary
- Ismail NA et al. [2018]. Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. Clinical
- Martinez E et al. [2018]. Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia. Clinical
- Ismail N et al. [2018]. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants. Clinical
- Chawla K et al. [2018]. Whole-genome sequencing reveals genetic signature of bedaquiline resistance in a clinical isolate of Mycobacterium tuberculosis. Clinical
- Ismail N et al. [2018]. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Clinical
- Minato Y et al. [2019]. Genomewide Assessment of Mycobacterium tuberculosis Conditionally Essential Metabolic Pathways. Mutant
- Ismail N et al. [2019]. Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance. Secondary
- Ismail NA et al. [2019]. Multicentre study to establish interpretive criteria for clofazimine drug susceptibility testing. Clinical
- Ismail N et al. [2019]. In Vitro Study of Stepwise Acquisition of rv0678 and atpE Mutations Conferring Bedaquiline Resistance. Secondary
- Ghodousi A et al. [2019]. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan. Clinical
- Peretokina IV et al. [2020]. Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates. Clinical
- Nieto Ramirez LM et al. [2020]. Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid. Review Clinical
- Singh BK et al. [2020]. Mutation in atpE and Rv0678 genes associated with bedaquline resistance among drug-resistant tuberculosis patients: A pilot study from a high-burden setting in Northern India. Regulation Clinical
- Ismail NA et al. [2020]. A Multimethod, Multicountry Evaluation of Breakpoints for Bedaquiline Resistance Determination. Clinical
- Yang J et al. [2020]. Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China. Clinical
- Nimmo C et al. [2020]. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Clinical
- Battaglia S et al. [2020]. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains. Clinical
- Degiacomi G et al. [2020]. In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates. Regulation Clinical
- Beckert P et al. [2020]. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era. Clinical
- Chengalroyen MD et al. [2020]. Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against Mycobacterium tuberculosis. Regulation
- Korol CB et al. [2020]. Tissue specific diversification, virulence and immune response to Mycobacterium bovis BCG in a patient with an IFN-γ R1 deficiency. Regulation Immunology Clinical
- Liu Y et al. [2021]. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China. Clinical
- Yoshiyama T et al. [2021]. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid. Clinical
- Liu Y et al. [2021]. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. Clinical
- Xu J et al. [2021]. Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Regulation Clinical
- Wang G et al. [2021]. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey. Clinical
- Zheng H et al. [2021]. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China. Clinical
- He W et al. [2021]. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China. Clinical
- Kaur P et al. [2021]. A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. Regulation Clinical
- Antoine R et al. [2021]. Intragenic Distribution of IS6110 in Clinical Mycobacterium tuberculosis Strains: Bioinformatic Evidence for Gene Disruption Leading to Underdiagnosed Antibiotic Resistance. Mutant Clinical
- Yao C et al. [2021]. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition. Clinical
- Vargas R et al. [2021]. Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex. Regulation
- Almeida D et al. [2021]. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Regulation Clinical
- Wu SH et al. [2021]. Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. Clinical
- Ismail N et al. [2021]. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Review Clinical
- Ismail NA et al. [2022]. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Clinical
- Goossens SN et al. [2022]. Detection of minor variants in Mycobacterium tuberculosis whole genome sequencing data. Clinical
- Omar SV et al. [2022]. Bedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations. Function
- Saeed DK et al. [2022]. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan. Clinical
- Park S et al. [2022]. Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Mycobacterium tuberculosis Isolates. Clinical
- Bainomugisa A et al. [2022]. Evolution and spread of a highly drug resistant strain of Mycobacterium tuberculosis in Papua New Guinea. Mutant Regulation Clinical
- Kabahita JM et al. [2022]. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda. Clinical
- Shi J et al. [2022]. Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients. Review Mutant Biochemistry
- Kobayashi M et al. [2022]. A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline. Clinical
- Chen X et al. [2022]. Identification of Mutations Associated With Macozinone-Resistant in Mycobacterium Tuberculosis. Clinical
- Kaniga K et al. [2022]. Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline. Function
- Guo Q et al. [2022]. Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in Mycobacterium tuberculosis. Regulation Clinical
- Trisakul K et al. [2022]. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant Mycobacterium tuberculosis isolates. Clinical
- Lagutkin D et al. [2022]. Genome-Wide Study of Drug Resistant Mycobacterium tuberculosis and Its Intra-Host Evolution during Treatment. Immunology Clinical
- Poulton NC et al. [2022]. Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis. Function
- Claassens M et al. [2022]. Whole-Genome Sequencing for Resistance Prediction and Transmission Analysis of Mycobacterium tuberculosis Complex Strains from Namibia. Regulation Clinical
- Singh K et al. [2022]. Mutation detection and minimum inhibitory concentration determination against linezolid and clofazimine in confirmed XDR-TB clinical isolates. Clinical
- Saeed DK et al. [2022]. Bedaquiline resistant Mycobacterium tuberculosis clinical isolates with and without rv0678 mutations have similar growth patterns under varying BDQ drug pressure. Clinical
- Almeida DV et al. [2023]. Mutations in Rv0678 Reduce Susceptibility of Mycobacterium tuberculosis to the DprE1 Inhibitor TBA-7371. Secondary
- Hu Y et al. [2023]. Investigation of bedaquiline resistance and genetic mutations in multi-drug resistant Mycobacterium tuberculosis clinical isolates in Chongqing, China. Clinical
- Limberis JD et al. [2023]. Circularization of rv0678 for Genotypic Bedaquiline Resistance Testing of Mycobacterium tuberculosis. Clinical
- Ismail N et al. [2023]. Emergence of Canonical and Noncanonical Genomic Variants following In Vitro Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine. Regulation
- Sonnenkalb L et al. [2023]. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. Mutant Regulation Clinical
- Shang Y et al. [2023]. Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients. Clinical
- An Q et al. [2023]. Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis. Review Clinical
- Perumal R et al. [2023]. Mycobacterium tuberculosis Intra-Host Evolution Among Drug-Resistant Tuberculosis Patients Failing Treatment. Clinical
- Xu J et al. [2023]. Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis. Regulation Proteomics Localization
- Otum CC et al. [2023]. Site-directed mutagenesis of Mycobacterium tuberculosis and functional validation to investigate potential bedaquiline resistance-causing mutations. Mutant Regulation
- Anlay DZ et al. [2023]. A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant. Secondary
- Snobre J et al. [2023]. Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678. Regulation Clinical
- Mok S et al. [2023]. Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates. Clinical
- Tong E et al. [2023]. Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China. Clinical
- Derendinger B et al. [2023]. Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. Clinical
- Islam MM et al. [2023]. Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis. Review Biochemistry Clinical
- Brown TS et al. [2024]. Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis. Clinical
- Nimmo C et al. [2024]. Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis. Review Clinical
- Umpeleva T et al. [2024]. Identification of genetic determinants of bedaquiline resistance in Mycobacterium tuberculosis in Ural region, Russia. Clinical
- Nimmo C et al. [2024]. Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis. Regulation Clinical
- Villellas C et al. [2024]. Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium tuberculosis mutants with increased MIC. Clinical
- Miotto P et al. [2024]. The exceptions that prove the rule-a historical view of bedaquiline susceptibility. Secondary
- Liu A et al. [2024]. Rapid detection of multidrug resistance in tuberculosis using nanopore-based targeted next-generation sequencing: a multicenter, double-blind study. Clinical
- Madadi-Goli N et al. [2024]. The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran. Clinical
- Yu W et al. [2024]. Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis. Secondary
- Farnia P et al. [2024]. The Role of Efflux Pumps transporter in Multi-drug Resistant Tuberculosis: Mycobacterial memberane protein(MmpL5). Regulation Immunology Clinical
- Akbari Aghababa A et al. [2024]. Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis. Clinical
- Katale BZ et al. [2024]. Clinical application of whole-genome sequencing in the management of extensively drug-resistant tuberculosis: a case report. Clinical
- Balgouthi K et al. [2024]. Mutations in Rv0678, Rv2535c, and Rv1979c Confer Resistance to Bedaquiline in Clinical Isolates of Mycobacterium Tuberculosis. Clinical
- Peng Y et al. [2024]. Phenotypic and genotypic analysis of drug resistance in M. tuberculosis isolates in Gansu, China. Mutant Biochemistry Regulation
- Ahmad Khosravi N et al. [2024]. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis. Review Clinical
- Snobre J et al. [2024]. Frameshift mutations in the mmpR5 gene can have a bedaquiline-susceptible phenotype by retaining a protein structure and function similar to wild-type Mycobacterium tuberculosis. Clinical
- Lounis N et al. [2024]. Mice infected with M. tuberculosis with Rv0678 mutations still benefit from bedaquiline treatment. Secondary
- Chen S et al. [2025]. In vitro monitoring of drug resistance emergence during stepwise induction of bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic analysis. Clinical
- Rashid F et al. [2025]. Investigation of bedaquiline heteroresistance among Mycobacterium tuberculosis isolates from Pakistan. Clinical
- Ardizzoni E et al. [2025]. Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from Armenia. Clinical
- Fountain AJ et al. [2025]. Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity. Biochemistry Regulation Clinical
- Li D et al. [2025]. Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis. Secondary
- Hu X et al. [2025]. Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis. Review Clinical
- Sonnenkalb L et al. [2025]. The mutant selection window of moxifloxacin and bedaquiline resistant Mycobacterium tuberculosis. Clinical
- Wang MD et al. [2025]. [Bedaquiline susceptibility and molecular mutation characteristics of Mycobacterium tuberculosis in Guizhou Province]. Clinical
- Adlard D et al. [2025]. An improved catalogue for whole-genome sequencing prediction of bedaquiline resistance in Mycobacterium tuberculosis using a reproducible algorithmic approach. Clinical
- Maghradze N et al. [2025]. Linking genetic and phenotypic bedaquiline resistance in Mycobacterium tuberculosis strains from Georgia. Clinical
- Schön T et al. [2025]. Quality control and considering systematic MIC shifts are key when evaluating the role of mmpR5 (Rv0678) frameshifts in bedaquiline resistance. Secondary
- Snobre J et al. [2025]. Reply to Schön et al., "Quality control and considering systematic MIC shifts are key when evaluating the role of mmpR5 (Rv0678) frameshifts in bedaquiline resistance". Secondary
- Ahmad Khosravi N et al. [2025]. Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran. Clinical
- Jiang X et al. [2025]. Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare. Regulation Clinical
- Rupasinghe P et al. [2025]. In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis. Secondary
- Fountain AJ et al. [2025]. Structural and functional analysis of the Mycobacterium tuberculosis MmpS5L5 efflux pump presages increased bedaquiline resistance. Regulation Clinical
- Ghodousi A et al. [2025]. Low-level BTZ-043 resistance in Mycobacterium tuberculosis and cross-resistance to bedaquiline and clofazimine. Clinical
- Balgouthi K et al. [2025]. Examination of Genetic Mutations of Clofazimine Resistance in Drug-Resistant Mycobacterium TB Isolates. Clinical
- Diriba G et al. [2025]. Whole genome sequencing-based detection of extensively drug-resistant tuberculosis from Ethiopia. Clinical
- Singh I et al. [2025]. Bedaquiline Resistance: A Looming Global Threat in Tuberculosis Management. Review Biochemistry Clinical
- Wang J et al. [2026]. Emergence of Rv0678 (mmpR5) mutations mediating resistance to bedaquiline and clofazimine in a liver transplant recipient with rifampicin-susceptible tuberculosis: A case report. Immunology Clinical
- Mosallam N et al. [2026]. Second-Generation Anti-Tubercular Squaramides Targeting Complex V of the Respiratory Chain of Mycobacterium tuberculosis Displaying Enhanced Metabolic Stability. Biochemistry
- Kaapu KG et al. [2026]. Bedaquiline Resistance in Drug-Resistant Tuberculosis in South Africa: A Systematic Review and Meta-Analysis of Emerging Trends. Review Clinical
- Sakhi H et al. [2026]. Global mapping of bedaquiline-resistant Mycobacterium tuberculosis: a systematic review. Review Clinical
- Malope P et al. [2026]. Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa. Clinical
- Vambe D et al. [2026]. Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing. Clinical
- Victor AS et al. [2026]. Phenotypic drug susceptibility testing and genotypic characterization of Bedaquiline resistance in drug resistant Mycobacteriumtuberculosis. Clinical
- Ushtanit A et al. [2026]. A Case of Transmission of Bedaquiline- and Linezolid-Resistant Tuberculosis. Clinical
- Luo M et al. [2026]. Comparative in vitro antimicrobial susceptibility profiles of clofazimine and pyrifazimine against clinical isolates of Mycobacterium tuberculosis in southwest China. Mutant Biochemistry Clinical
- Aguilar-Ayala DA et al. [2026]. In vitro pharmacokinetics and pharmacodynamics of the diarylquinoline TBAJ-587 and its metabolites against Mycobacterium tuberculosis. Biochemistry Clinical
- Ngema SL et al. [2026]. Rapid detection of treatment-emergent resistance to bedaquiline and pretomanid in Mycobacterium tuberculosis using TM4::GeNL reporter mycobacteriophages. Clinical
- Muhammad N et al. [2026]. Mutational profiling of ESX/type VII secretion system-associated genes in drug-resistant Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. Clinical
- Sineke N et al. [2026]. Translating drug-resistant tuberculosis surveillance into molecular-biophotonic diagnostic innovation in rural Eastern Cape, South Africa. Clinical
- Kaapu KG et al. [2026]. Emergence and characterisation of bedaquiline, pretomanid and linezolid resistance in recurrent rifampicin-resistant tuberculosis patient: A case report. Clinical
- Wang Q et al. [2026]. Long-read sequencing of clinical multidrug-resistant Mycobacterium tuberculosis reveals a novel ethA structural variant conferring ethionamide resistance. Mutant Clinical